round button
Leave a message

中東およびアフリカの脳腫瘍診断市場 – 2030 年までの業界動向と予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

中東およびアフリカの脳腫瘍診断市場 – 2030 年までの業界動向と予測

  • Medical Devices
  • Published Report
  • Feb 2023
  • MEA
  • 350 ページ
  • テーブル数: 65
  • 図の数: 35

中東およびアフリカの脳腫瘍診断市場

Market Size in USD Billion

CAGR :  % Diagram

Diagram 予測期間
2024 –2030
Diagram 市場規模(基準年)
USD MILLION
Diagram Market Size (Forecast Year)
USD 244.87
Diagram CAGR
%
Diagram 主要市場プレーヤー
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

中東およびアフリカの脳腫瘍診断市場、検査タイプ別(画像検査、生検、腰椎穿刺、分子検査、脳波検査など)、がんの種類別(聴神経腫、星状細胞腫、多形性神経膠芽腫、髄膜腫、乏突起膠腫など)、年齢層別(21歳未満、21~34歳、35~65歳、65歳以上)、エンドユーザー別(病院、専門クリニック、診断センターおよび研究機関、外来手術センターなど)、業界動向および2030年までの予測。

中東およびアフリカの脳腫瘍診断市場

中東およびアフリカの脳腫瘍診断市場の分析と規模

脳腫瘍診断市場の成長を牽引する主な要因の 1 つは、世界中で脳腫瘍の症例が増加していることです。より良い治療法を求めて複数の企業が継続的に臨床試験研究を実施していることが、市場の拡大につながっています。市場は、脳腫瘍の早期診断に対する意識の高まりや、脳腫瘍細胞への薬物送達の革新にも影響を受けています。しかし、脳腫瘍の診断と治療にかかる費用の高さ、脳腫瘍の診断が遅れて予後が悪くなること、治療薬と治療法の副作用が、予測期間中の中東およびアフリカの脳腫瘍診断市場の抑制要因となっています。

中東およびアフリカの脳腫瘍診断市場

中東およびアフリカの脳腫瘍診断市場

一方、新興企業による投資と資金の増加、がん診断に向けた政府の取り組み、医療費の増加は、市場の成長の機会として機能します。しかし、診断製品に対する厳格な規制要件と、診断テストの実施時に直面する運用上の障壁は、中東およびアフリカの脳腫瘍診断市場に課題をもたらします。

脳腫瘍診断製品の需要は、画像技術の向上により中東およびアフリカで増加するでしょう。さまざまな企業が、徐々に市場の成長につながる取り組みを行っています。

中東およびアフリカの脳腫瘍診断市場は、2023年から2030年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2023年から2030年の予測期間に16.9%のCAGRで成長し、2030年までに2億4,487万米ドルに達すると予測しています。

レポートメトリック

詳細

予測期間

2023年から2030年

基準年

2022

歴史的な年

2021 (2020~2016年にカスタマイズ可能)

定量単位

収益(百万米ドル)

対象セグメント

検査の種類 (画像検査、生検、腰椎穿刺、分子検査、脳波検査など)、がんの種類 (聴神経腫、星状細胞腫、多形性神経膠芽腫、髄膜腫、乏突起膠腫など)、年齢層 (21 歳未満、21 ~ 34 歳、35 ~ 65 歳、65 歳以上)、エンド ユーザー (病院、専門クリニック、診断センターおよび研究機関、外来手術センターなど)。

対象国

South Africa, Saudi Arabia, UAE, Egypt, Kuwait, and the rest of the Middle East and Africa

Market Players Covered

Siemens Healthcare GmbH, NIHON KOHDEN CORPORATION., FUJIFILM Holdings Corporation, Neusoft Corporation, GE HealthCare, Koninklijke, Philips N.V., and BD, among others

Market Definition

Brain cancer is an overgrowth of cells in the brain that forms masses called tumors. It is a brain disorder in which cancer cells (malignant cells) arise in the brain tissue. Cancer cells multiply to produce a mass of cancer tissue (tumor) that interferes with brain functions such as muscle control, sensation, memory, and other body functions. Cancer cells that arise from brain tissue are called primary brain tumors, while tumors that spread from other body parts to the brain are called metastatic or secondary brain tumors.

Primary brain tumors can develop from various brain tissues (for example, glial cells, astrocytes, and other brain cell types). Metastatic brain cancer is caused by the spread of cancer cells from a body organ to the brain.

Middle East and Africa Brain Cancer Diagnostic Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

  • Rising Cases of Brain Cancer Worldwide

Cancer that develops elsewhere in the body & then spreads into the brain is called a secondary brain tumor or brain metastasis. There are various cancers that can metastasize into the brain, such as breast cancer, lung cancer, colon cancer and kidney cancer. Brain cancer cells generally do not spread beyond the brain. Rather, they have the capacity to travel short distances within the brain. Genetic links inherited through family ancestors, chemical exposure to certain industrial chemicals or solvents, compromised immune system, and previous radiation treatments can be some of the major causes of brain cancer.

Brain cancer cases are rising worldwide. In 2019, as per the National Cancer Institute report, there were an estimated 176,566 people found living with brain & other nervous system cancer in the United States. In addition, based on 2017-2019 data, it has been predicted that approximately 0.6 percent of men & women will be diagnosed with brain and other nervous system cancer at some point during their lifetime.

  • Rising awareness of the early diagnosis of brain cancer

Brain cancer awareness month is nationally recognized in the United States during the month of May. This awareness month focuses on bringing together the brain tumor community to increase awareness among the patient population.

Brain cancer is not a common type of cancer like other types. However, the need for new & innovative ways to treat brain cancer is more important. As per research studies, 1.4 million patients worldwide are suffering from malignant brain tumors & another 2, 56,000 people will be diagnosed with a malignant brain tumor by the end of the year.

The importance of patient care, education & cancer research is becoming more apparent due to the impact of COVID-19 worldwide. Considering the future perspectives, there is still more groundwork to be done to discover new drugs & effective approaches for brain cancer patients. Brain cancer awareness month is a movement that is fully dedicated to these efforts and even in the midst of a pandemic.

Opportunities

  • Increasing investment and funding by emerging players

The market for brain cancer is huge, and the rising number of the population affected by this disease is attracting other players to work in the diagnostic field for this disease. Diagnosis of brain cancer in the early stage is a tedious task but can be possible with the new product line for the diagnosis of disease.

The industry offers numerous growth opportunities. Thus, a number of start-ups providing innovative products and technologies have been entering the market. Many new companies and start-ups are looking forward to the field of brain cancer. They are trying to make business expansion and increase the distribution of their newly marketed product. Some of the company are listed below and is expected to act as an opportunity for a brain cancer diagnosis.

  • Government initiatives toward cancer diagnostics

The government plays a major role while taking the initiative for cancer diseases because cancer is a leading disease across the globe. Cancer has increased very briskly in people in past decades. There were 9,555,027 cases of deaths attributable to Middle East and Africa cancers in 2018, of which 241,037 (2.71%) belonged to brain cancers.

The government all around the globe is actively engaged in taking several initiatives towards cancer, specifically brain cancer diagnostics, in order to increase awareness among the people regarding the cancerous disease. Government and Nongovernment organizations funded 57% of therapy-oriented biology and drug development, with 7% to prevention and 13% to early detection, diagnosis and prognosis of cancer disease. These government initiatives towards cancer diagnostics are boosting the demand of the market.

Restraints/Challenges

  • High cost associated with diagnosis & treatment for brain cancer

The brain is the most important part of our body, the organ which generates our memories and emotions, as well as containing our skills and expertise. Therefore, cancer of the brain is uniquely destructive. The changes a brain tumor can cause in cognition, behavior and personality result in high economic costs, which are borne by individuals, health systems (direct medical costs) and the wider public purse (direct non-medical costs and indirect costs).

The average cost of brain tumor surgery in western countries is very high. The costs associated with each type of treatment will vary depending on the specific procedure, location, and tumor severity. A study published in the journal Cancer found that brain cancer patients and their families bore a significantly higher economic burden than those affected by other types of cancer. Brain cancer patients had the highest indirect costs, at an average of USD 64,790 per year. Hence, the high cost associated with the diagnosis & treatment of brain cancer may restrain the market growth.

  • Operational Barriers Faced in Conducting Diagnostics Tests

Recent advances in the field of brain cancer diagnostics may be related to the kits, instruments, reagents, control or any other. It is not easy to change the adaptability of healthcare professionals with advancement. In order to make the structural decisions and précised results in diagnostics, organizations need to conduct a training session for the healthcare professionals to overcome and avoid errors in diagnosis.     

Rural, developing, and low-income countries in the different regions do not have enough infrastructure to maintain the new kits and for the sample storage as well. This is because of the limited supply of electricity and lack and education and awareness among healthcare professionals in the handling of new kits and reagents. This leads to errors in the diagnosis results and can lead to certain deaths, and can become a threat to the carrier of the individual performing the test.

These barriers related to conducting the cancer diagnostics test may affect the life of the populations. This is one of the most difficult parts to overcome with respect to low-income countries. Thus, this is affecting the diagnostics community and acting as a challenge for the Middle East and Africa brain cancer diagnostic market.

Post-COVID-19 Impact on the Middle East and Africa Brain Cancer Diagnostic Market

The COVID-19 pandemic had a great impact on the brain cancer diagnostics and surgical industries. Trade groups in the cancer diagnostic products sector claim that the Middle East and Africa supply chain for diagnostic products has been significantly damaged, impacting end-user consumption of the brain cancer diagnostic market. Sales of diagnostics products in the first quarter of 2020 were significantly delayed due to logistical and transportation issues. On the demand side, the market is increasing as people have to get diagnosed after the lockdown scenario. The situation needs to be taken into consideration, and emergency diagnostics need to be done. Furthermore, on the supply side, the growth of the market is on a negative scale. This is due to the lockdown situations in many countries manufacturing diagnostic, operating and cancer care instruments.

診断製品の供給は、中東およびアフリカでのCOVID-19パンデミックにより大きな打撃を受けています。この供給減少は、主に世界各国が採用しているさまざまな検疫政策によるものです。これは、移動制限や労働力削減とともに、診断機器追跡システムの供給市場の減少傾向の主な理由です。これは医療機器の品質と有効性に大きな影響を与えています。多くの国の既存の製品輸出政策は、供給と需要の比率のバランスを崩しています。COVID-19の罹患による労働力の減少は、脳腫瘍診断製品の供給減少に寄与するもう1つの要因です。

最近の動向

  • 2022 年 11 月、シーメンス ヘルスケア GmbH は、臨床および科学研究用に設計された最新の磁気共鳴断層撮影装置 2 台を発表しました。高い磁場強度と強力な勾配性能により、両方のスキャナーは体内の最も微細な構造をより鮮明に検出するのに最適です。
  • 2022年11月、BDは、がん臨床試験における多様性、公平性、包括性を高めるために、Valley-Mount Sinai Comprehensive Cancer Careに652,000米ドルを助成すると発表しました。

中東およびアフリカの脳腫瘍診断市場の範囲

中東およびアフリカの脳腫瘍診断市場は、検査タイプ、がんの種類、年齢層、エンドユーザーに分類されています。これらのセグメントの成長は、業界のわずかな成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供して、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。

テストの種類

  • 画像検査
  • 生検
  • 腰椎穿刺
  • 分子検査
  • 脳波検査(EEG)
  • その他

検査の種類に基づいて、中東およびアフリカの脳腫瘍診断市場は、画像検査、生検、腰椎穿刺、分子検査、脳波検査(EEG)などに分類されます。

がんの種類

  • 聴神経腫瘍
  • 星細胞腫
  • 多形性膠芽腫
  • 髄膜腫
  • 乏突起膠腫
  • その他

がんの種類に基づいて、中東およびアフリカの脳腫瘍診断市場は、聴神経腫瘍、星細胞腫、多形性神経膠芽腫、髄膜腫、乏突起膠腫などに分類されます。

年齢層

  • 21歳未満
  • 21-35
  • 35-65
  • 65歳以上

年齢層に基づいて、中東およびアフリカの脳腫瘍診断市場は、21 歳未満、21 ~ 34 歳、35 ~ 65 歳、65 歳以上に分類されます。

エンドユーザー

エンドユーザーに基づいて、中東およびアフリカの脳腫瘍診断市場は、病院、専門クリニック、診断センター、研究機関、外来手術センターなどに分類されます。

脳腫瘍診断市場

中東およびアフリカの脳腫瘍診断市場の地域分析/洞察  

中東およびアフリカの脳腫瘍診断市場が分析され、市場規模の洞察と傾向が国、検査の種類、がんの種類、年齢層、エンドユーザー別に提供されます。

中東およびアフリカの脳腫瘍診断市場は、南アフリカ、サウジアラビア、UAE、エジプト、クウェート、およびその他の中東およびアフリカの国々で構成されています。

  • 2023年には、消費者の間で脳腫瘍診断の利点についての認識が高まっているため、南アフリカが中東およびアフリカの脳腫瘍診断市場を支配すると予想されています。脳腫瘍診断製品の需要の増加と業界における研究開発活動の増加も、予測期間中に市場を牽引すると予想されます。

競争環境と中東およびアフリカの脳腫瘍診断市場シェア分析

脳腫瘍診断市場の競争状況は、競合他社による詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、中東およびアフリカでのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、中東およびアフリカの脳腫瘍診断市場への会社の重点にのみ関連しています。

この市場で活動している主要企業としては、日本光電工業、富士フイルムホールディングス、Neusoft Corporation、GE HealthCare、Koninklijke Philips NV、BD、FONAR Corp.などが挙げられます。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 EPIDEMIOLOGY

6 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT

7 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS

7.1 REGULATORY SCENARIO IN THE U.S

7.2 REGULATORY SCENARIO IN AUSTRALIA

7.3 REGULATORY SCENARIO IN JAPAN

7.4 REGULATORY SCENARIO IN CHINA

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE

8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER

8.1.3 IMPROVED IMAGING TECHNIQUES

8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS

8.2 RESTRAINTS

8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER

8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES

8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS

8.3 OPPORTUNITIES

8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS

8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC

8.3.3 RISING HEALTHCARE EXPENDITURE

8.4 CHALLENGES

8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS

8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS

9 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE

9.1 OVERVIEW

9.2 IMAGING TEST

9.2.1 CT SCAN

9.2.2 MRI

9.2.3 PET

9.2.4 OTHERS

9.3 MOLECULAR TESTING

9.4 ELECTROENCEPHALOGRAPHY (EEG)

9.5 LUMBAR PUNCTURE

9.6 BIOPSY

9.6.1 OPEN BIOPSY

9.6.2 STEREOTACTIC BIOPSY

9.6.3 NEEDLE BIOPSY

9.6.4 NEUROENDOSCOPY

9.7 OTHERS

10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE

10.1 OVERVIEW

10.2 GLIOBLASTOMA MULTIFORME

10.3 MENINGIOMAS

10.4 ASTROCYTOMAS

10.5 ACOUSTIC NEUROMA

10.6 OLIGODENDROGLIOMA

10.7 OLIGODENDROGLIOMA

10.8 OTHERS

11 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP

11.1 OVERVIEW

11.2 35-65

11.3 65 AND ABOVE

11.4 BELOW 21

11.5 21-34

12 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.3 SPECIALTY CLINICS

12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES

12.5 AMBULATORY SURGICAL CENTERS

12.6 OTHERS

13 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY REGION

13.1 MIDDLE EAST AND AFRICA

13.1.1 SOUTH AFRICA

13.1.2 SAUDI ARABIA

13.1.3 U.A.E.

13.1.4 KUWAIT

13.1.5 EGYPT

13.1.6 REST OF MIDDLE EAST AND AFRICA

14 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

15 SWOT ANALYSIS

16 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE

16.1 KONINKLIJKE PHILIPS N.V.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 CANON INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 SIEMENS HEALTHCARE GMBH

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 BD

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 NIHON KOHDEN CORPORATION.

16.5.1 COMPANY SNAPSHOT

16.5.2 RECENT FINANCIALS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 BIOCEPT, INC.

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENT

16.7 BIOMIND

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENT

16.8 CEREBRAL DIAGNOSTIC

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 DXCOVER LIMITED

16.9.1 COMPANY SNAPSHOT

16.9.2 PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 FONAR CORP.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 FUJIFILM CORPORATION

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 GE HEALTHCARE.

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 HITACHI, LTD.

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 MINFOUND MEDICAL SYSTEMS CO.,

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENT

16.15 NANTOMICS.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 NEUSOFT CORPORATION

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 SEQUOIA HEALTHCARE.

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT

16.18 STERNMED GMBH

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

16.19 THERMO FISHER SCIENTIFIC INC.

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT

16.2 TIME MEDICAL HOLDING.

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS

表のリスト

TABLE 1 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 35 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 36 SOUTH AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 37 SOUTH AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 38 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 39 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 40 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 41 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 42 SAUDI ARABIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 43 SAUDI ARABIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 44 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 45 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 46 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 47 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 48 U.A.E. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 49 U.A.E. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 50 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 51 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 52 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 53 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 54 KUWAIT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 55 KUWAIT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 56 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 57 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 58 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 59 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 60 EGYPT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 61 EGYPT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 62 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 63 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 64 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 65 REST OF MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

図表一覧

FIGURE 1 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID

FIGURE 10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030

FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET

FIGURE 14 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022

FIGURE 15 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 17 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022

FIGURE 19 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 21 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022

FIGURE 23 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 25 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022

FIGURE 27 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)

FIGURE 29 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)

FIGURE 31 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)

FIGURE 32 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)

FIGURE 33 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)

FIGURE 34 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)

FIGURE 35 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The Middle East and Africa Brain Cancer Diagnostic Market is projected to grow at a CAGR of 16.9% during the forecast period by 2030.
The future market value of the Middle East and Africa Brain Cancer Diagnostic Market is expected to reach USD 244.87 million by 2030.
The major players in the Middle East and Africa Brain Cancer Diagnostic Market are Siemens Healthcare GmbH, NIHON KOHDEN CORPORATION., FUJIFILM Holdings Corporation, Neusoft Corporation, GE HealthCare, Koninklijke, Philips N.V., and BD, among others.
The countries covered in the Middle East and Africa Brain Cancer Diagnostic Market are South Africa, Saudi Arabia, UAE, Egypt, Kuwait, and the rest of the Middle East and Africa.
a